Business
Xenetic Biosciences, Inc. Announces Research and Development Collaboration with Scripps Research to Advance XCART(TM) Platform
- Represents significant milestone in strategic development plan to advance XCART through academic collaborations - - Provides access to leading research
About this update from Xenetic Biosciences, Inc.
[{"type":"text","content":"- Represents significant milestone in strategic development plan to advance XCART through academic collaborations - - Provides access to leading research institution with world renowned immunology expertise - - Company engaged in ongoing discussions to potentially add additional academic and development collaborators -FRAMINGHAM, MA / ACCESSWIRE / May 19, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (\"Xenetic\" or the \"Company\"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today it has entered into a research funding and option agreement (\"the Agreement\") with Scripps Research to advance the development of the XCART™ technology for B cell malignancies.The XCART platform is a significantly differentiated, proprietary approach to personalized CAR T therapy for the treatment of multiple tumor types of B-cell Non-Hodgkin lymphomas, and was originally developed by Scripps Research in collaboration with the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry. XCART is believed to have the potential to significantly enhance the safety and efficacy of cell therapy for B-cell lymphomas by generating patient- and tumor-specific CAR T cells.\"We are thrilled to partner with Scripps Research to aid in the development of XCART. Not only are they a leading, world renowned research and development organization, but they are also one of the original developers of the XCART platform,\" commented Jeffrey Eisenberg, Chief Executive Officer of Xenetic. \"We believe that the team at Scripps Research, given their deep knowledge and understanding of the XCART platform, is uniquely qualified to guide key aspects of our preclinical development program. They will also provide method development expertise as the program moves towards process development for clinical manufacturing. We expect this collaboration to be one of the integral elements in our strategy of leveraging academic and development partners to provide operational efficiencies as we drive XCART toward clinical manufacturing and ultimately first-in-human studies.\"The XCART technology platform was designed to utilize an established screening technique to identify polypeptide domains that selectively bind to the unique B-cell receptor (\"BCR\") on the surfac...